<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807348</url>
  </required_header>
  <id_info>
    <org_study_id>CGZ303</org_study_id>
    <nct_id>NCT04807348</nct_id>
  </id_info>
  <brief_title>Chiglitazar Added to Metformin for Type 2 Diabetes</brief_title>
  <official_title>A Randomised Double-blind Placebo Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Chiglitazar Added to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy (RECAM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chipscreen Biosciences, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chipscreen Biosciences, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type&#xD;
      2 diabetes Inadequately controlled with metformin Monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a multi-center, randomized, double-blind, placebo parallel control&#xD;
      design, and uses superiority test to determine whether the experimental group is superior to&#xD;
      the control group in terms of main efficacy endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of HbA1c change from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>central lab test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood fasting plasma glucose level from baseline</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>central lab test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of HOMA-the IR value from baseline</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>model calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of blood lipids level from baseline</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>includeing TC, LDL-C, HDL-C, VLDL-C, non-HDL-C, TG, FFA, ApoA1, ApoB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of AEs</measure>
    <time_frame>28 weeks</time_frame>
    <description>safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with lab abnormality</measure>
    <time_frame>24 weeks</time_frame>
    <description>number or rate of founds in lab tests</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">519</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Chiglitazar sodium 32mg QD+metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chiglitazar 32mg qd+metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chiglitazar sodium 48 mg QD+metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chiglitazar 48 mg qd+metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo+metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chiglitazar 32mg</intervention_name>
    <description>Administrated once daily</description>
    <arm_group_label>Chiglitazar sodium 32mg QD+metformin</arm_group_label>
    <other_name>Bilessglu</other_name>
    <other_name>CS038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chiglitazar 48mg</intervention_name>
    <description>Administrated once daily</description>
    <arm_group_label>Chiglitazar sodium 48 mg QD+metformin</arm_group_label>
    <other_name>CS038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Chiglitazar</description>
    <arm_group_label>placebo+metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>most tolerable dose</description>
    <arm_group_label>Chiglitazar sodium 32mg QD+metformin</arm_group_label>
    <arm_group_label>Chiglitazar sodium 48 mg QD+metformin</arm_group_label>
    <arm_group_label>placebo+metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ) Provide a signed and dated informed consent form;&#xD;
&#xD;
          2. ) Men and women aged ≥ 18 years and ≤ 75 years;&#xD;
&#xD;
          3. ) According to the World Health Organization ( the WHO ) 1999 criteria for the&#xD;
             diagnosis of type 2 diabetes;&#xD;
&#xD;
          4. ) After metformin stable dose monotherapy (≥1500 mg/day or maximum tolerated dose, but&#xD;
             the maximum tolerated dose not &lt; l000 mg/day) for at least 8 weeks;&#xD;
&#xD;
          5. ) The local HbA1c value during the screening period: 7.5% ≤ HbA1c ≤ 11% ;&#xD;
&#xD;
          6. ) The HbA1c value of the central laboratory before randomization: 7.0% ≤ HbA1c ≤ 10.5%&#xD;
             ;&#xD;
&#xD;
          7. ) BMI ≥ 18.5 kg/m2 and ≤ 35 kg/m 2 ;&#xD;
&#xD;
          8. ) Fasting C- peptide ≥ 0.5 nmol/L ;&#xD;
&#xD;
          9. ) Women of Childbearing Potential ( WOCBP ) should take reliable contraceptive&#xD;
             measures at least 1 month before the screening, during the entire trial, and within 3&#xD;
             months after completing the trial; male subjects should take reliable contraceptive&#xD;
             measures to avoid making their sexual partners to pregnant during the entire trial and&#xD;
             within 3 months after the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ) Type 1 diabetes;&#xD;
&#xD;
          2. ) Pregnancy or lactation;&#xD;
&#xD;
          3. ) The New York Heart Association (NYHA ) defines congestive heart failure as grade III&#xD;
             or IV ;&#xD;
&#xD;
          4. ) Significant history of cardiovascular and cerebrovascular diseases within 6 months&#xD;
             before screening, defined as myocardial infarction, coronary artery bypass graft or&#xD;
             angioplasty, valvular disease or repair, unstable angina, transient brain Ischemic&#xD;
             attack, or cerebrovascular accident;&#xD;
&#xD;
          5. ) Suffered from malignant tumors (except cured basal cell carcinoma) within 5 years&#xD;
             before screening;&#xD;
&#xD;
          6. ) Edema of lower limbs or edema of the whole body;&#xD;
&#xD;
          7. ) Moderate to severe renal insufficiency [ Calculated eGFR&lt;60 ml/ ( min*1.73m2 ) using&#xD;
             CKD - EPI formula ];&#xD;
&#xD;
          8. ) urinary albumin-to-creatinine ratio of &gt; 300 mg /g;&#xD;
&#xD;
          9. ) Triglyceride&gt; 5.6 mmol /L;&#xD;
&#xD;
         10. ) Active liver disease and /or obvious liver function abnormalities, defined as&#xD;
             AST&gt;2.5 times the upper limit of normal value and/or ALT&gt;2.5 times the upper limit of&#xD;
             normal value and/or total bilirubin &gt;1.5 times the normal value Upper limit&#xD;
&#xD;
         11. ) Clinically significant arrhythmias in the electrocardiogram examination and&#xD;
             treatment or intervention are required. The investigator judges that it is not&#xD;
             suitable to participate in this clinical trial;&#xD;
&#xD;
         12. ) Human immunodeficiency virus (HIV) antibody-positive; Treponema pallidum antibody&#xD;
             positive; positive hepatitis B surface antigen and HBV DNA quantification values were&#xD;
             higher than the upper; HCV antibodies and HCV RNA quantification values were higher&#xD;
             than the upper ;&#xD;
&#xD;
         13. ) History of illegal drug abuse within 12 months before screening ;&#xD;
&#xD;
         14. ) Participated in other clinical trials within 90 days before screening ;&#xD;
&#xD;
         15. ) Donated whole blood, plasma, or platelets within 3 months before screening.&#xD;
&#xD;
         16. ) Before randomization, the investigator judged that the subjects had poor compliance&#xD;
             with the study protocol or drug treatment, defined as the subjects taking less than&#xD;
             80% or more than 120% of the prescribed dose of chiglitazar/ placebo or metformin;&#xD;
&#xD;
         17. ) The investigator judged that it is not suitable to participate in this clinical&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linong Ji, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linong Ji, Prof.</last_name>
    <phone>8610-88326666</phone>
    <email>plum_jj@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hefei Second People's Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Dai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianrong Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yijishan Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialin Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guang Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingxia Yuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinkui Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Chang Gung Memorial Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianzhong Xiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junqing Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese People's Liberation Army Rocket Army Characteristic Medical Center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanmin Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linong Ji</last_name>
      <email>plum_jj@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangling Xiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Three Gorges Hospital Affiliated to Chongqing University</name>
      <address>
        <city>Wanzhou</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijuan Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijing Jia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Shenzhen Hospital of Huazhong University of Science and Technology</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libo Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harrison International Peace Hospital</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianlin Geng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihui Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukun Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huaihe Hospital of Henan University</name>
      <address>
        <city>Kaifeng</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wuyan Pang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liujun Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Luoyang City</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junhang Tian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinxiang Central Hospital</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanghong Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Chenzhou City</name>
      <address>
        <city>Chenzhou</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihong Song</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yueyang Second People's Hospital</name>
      <address>
        <city>Yueyang</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenli Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhuzhou Central Hospital</name>
      <address>
        <city>Zhuzhou</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohong Lin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Baotou Steel Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meiying Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Huai'an</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiping Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Provincial People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yibing Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yifu Hospital Affiliated to Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changjiang Ying</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Harbin</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guixia Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhifeng Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Harbin</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanqing Cai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panjin Liaoyou Baoshihua Hospital</name>
      <address>
        <city>Panjin</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolin Dong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jining Medical College, Shandong Province</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Ban</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao University Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yangang Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gongli Hospital, Pudong New Area, Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingjun Gu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Minhang District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialin Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pudong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongxiang Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Seventh People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Yuncheng City, Shanxi Province</name>
      <address>
        <city>Yuncheng</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tangshan Workers' Hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Fang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huzhou Central Hospital</name>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Qiu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.sciencedirect.com/science/article/abs/pii/S2095927321001687</url>
    <description>Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S2095927321002383</url>
    <description>Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)</description>
  </link>
  <reference>
    <citation>Linong Ji, Weihong Song, Hui Fang, Wei Li, Jianlin Geng, Yangang Wang, Lian Guo, Hanqing Cai, Tao Yang, Hongmei Li, Gangyi Yang, Qifu Li, Kuanzhi Liu, Shuying Li, Yanjun Liu, Fuyan Shi, Xinsheng Li, Xin Gao, Haoming Tian, Qiuhe Ji, Qing Su, Zhiguang Zhou, Wenbo Wang, Zunhai Zhou, Xuejun Li, Yancheng Xu, Zhiqiang Ning, Haixiang Cao, Desi Pan, He Yao, Xianping Lu, Weiping Jia, Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP), Science Bulletin, Volume 66, Issue 15, 2021, Pages 1571-1580, ISSN 2095-9273, https://doi.org/10.1016/j.scib.2021.03.019.</citation>
  </reference>
  <reference>
    <citation>Weiping Jia, Jianhua Ma, Heng Miao, Changjiang Wang, Xiaoyue Wang, Quanmin Li, Weiping Lu, Jialin Yang, Lihui Zhang, Jinkui Yang, Guixia Wang, Xiuzhen Zhang, Min Zhang, Li Sun, Xuefeng Yu, Jianling Du, Bingyin Shi, Changqing Xiao, Dalong Zhu, Hong Liu, Liyong Zhong, Chun Xu, Qi Xu, Ganxiong Liang, Ying Zhang, Guangwei Li, Mingyu Gu, Jun Liu, Guoyue Yuan, Zhaoli Yan, Dewen Yan, Shandong Ye, Fan Zhang, Zhiqiang Ning, Haixiang Cao, Desi Pan, He Yao, Xianping Lu, Linong Ji, Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS), Science Bulletin, Volume 66, Issue 15, 2021, Pages 1581-1590, ISSN 2095-9273, https://doi.org/10.1016/j.scib.2021.02.027.</citation>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

